Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

Posted On: 2019-12-12 22:30:43


Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company and Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Equillium had originally secured exclusive rights to develop and commercialize Biocon's novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

"Biocon is pleased with the development progress of itolizumab achieved by Equillium so far and has agreed to include Australia and New Zealand within the scope of the licensing agreement. As an innovation-led organization we are committed to bring novel therapeutics to the market to address unmet patient needs across the world. We look forward to our continued partnership with Equillium as they develop this molecule further for the treatment of severe autoimmune and inflammatory disorders," said Siddharth Mittal, CEO and Joint Managing Director, Biocon.

"We are pleased to deepen our relationship with Biocon by expanding our licensing agreement for itolizumab. Securing these rights helps strengthen and build upon our existing presence in Australia and New Zealand where we are collaborating with distinguished asthma centers and specialists to conduct the EQUIP clinical trial in uncontrolled asthma patients," said Bruce Steel, President and Chief Business Officer of Equillium.

Itolizumab is a novel first-in-class humanized anti-CD6 monoclonal antibody, which Biocon developed and launched in India under the brand name ALZUMAb™ to treat moderate to severe plaque psoriasis in 2013. In 2017, Biocon partnered with Equillium for this promising asset to develop it for a wide range of autoimmune disorders.

In addition to the EQUIP trial in uncontrolled asthma, Equillium is conducting Phase 1b proof-of-concept clinical trials of itolizumab for the treatment of acute graft-versus-host disease (aGVHD) and lupus nephritis. The U.S. Food and Drug Administration (FDA) granted itolizumab Fast Track designation for the treatment of aGVHD and lupus nephritis, as well as Orphan Drug designations for both the prevention and treatment of aGVHD.

Shares of BIOCON LTD. was last trading in BSE at Rs.293 as compared to the previous close of Rs. 290.4. The total number of shares traded during the day was 330364 in over 2829 trades.

The stock hit an intraday high of Rs. 294.2 and intraday low of 287.2. The net turnover during the day was Rs. 95834357.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Aarti Drugs Ltd board fixes Oct 1, 2020 as record date for bonus issue

Mphasis Ltd board to consider Q2 results on Oct 22, 2020

Acuite Rating assigns credit rating to Eros International Media Limited

HSIL Ltd Board approves Buy back of equity shares through market purchase

TCS receives Three Brandon Hall Awards for Talent Management & Excellence in Learning

ICRA reaffirms credit rating for enhanced debt limits of The Ramco Cements Ltd

Shree Renuka Sugars Ltd board allots shares to Wilmar Sugar Holdings Pte Ltd

Karda Constructions Limited commences construction work of Destination One Mall

Singoli-Bhatwari Hydel Power Plant, Uttarakhand - Spinning of Turbines commences today

Shankar Lal Rampal Dye-Chem Ltd board recommends 1:3 bonus issue

Canara Bank board to consider raising capital through QIP

Amrutanjan is Official Pain Relief Partner-Digital for Chennai Super Kings

Camlin Fine Sciences Limited commences commercial production at Dahej unit

RITES Ltd bags Railway Electrification project of Rs. 474.92 crore

SBI Card collaborates with Google to enable cardholders to make payments through Google Pay

TCS' Blockchain Product Quartz™ is now available on Microsoft Azure

Ramco Systems signs agreement with CHI Aviation

Steel Strips Wheels Ltd receives export orders of nearly 10000 wheels

Saregama launches Carvaan Malayalam with 5000 pre-loaded evergreen Malayalam song and Carnatic music

Momentive Quartz Technologies (MQT) Selects Kellton Tech to Implement SAP S/4HANA

HCL Technologies announces intent to acquire leading Australian IT Solutions Company, DWS Limited

GOCL Corporation Limited's UK subsidiary to sell partial stake in Quaker Houghton for $35 mn

Sonata Launches 'CSK 2020 Edition' for Chennai Superkings Fans

Universal Cables Ltd updates on capacity expansion

Innovators Facade Systems Limited receives work order of Rs. 26 crores

MRPL shareholders approve proposal to raise funds of Rs. 5000 crore

ITC Ltd increases stake in Delectable Technologies Pvt Ltd

PNB associate bank, JSC Tengri Bank's License revoked

ITC Ltd.'s Sunfeast YiPPee!'s 10th Anniversary celebrations make a GUINNESS WORLD RECORDS® achievement

RITES Ltd board approves buy back through tender offer at Rs. 265

Route Mobile Limited shares to list on Monday - Sep 21, 2020

Mysore Petro Chemicals Limited to write-off GBP 770,000

Somany Ceramics adds a dash of style at T2, Mumbai Airport.

United Spirits Ltd announces resignation of CFO

Lords Chloro Alkali Ltd posts loss of Rs. 1.08 crore in Q1FY21

Zydus Cadila receives final approval from USFDA for Potassium Chloride Extended-Release Tablets

ICRA upgrades rating of Escorts Ltd

Bhatia Mobile to Migrate to main board of BSE

Avantel Ltd receives order of Rs. 15.97 crore from Bharat Electronics Ltd

Magna Electro Castings Ltd board approves buy back at Rs. 175

TATA Tea Chakra Gold Becomes Official Tea Partner for Chennai Super Kings in IPL 2020

Tiger Logistics India Limited provides future Business Outlook

Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® Capsules patent litigation with Celgene

TVS Motor Company expands and strengthens its presence in Colombia

ICICI Securities successfully closes ~INR 6,000 mm IPO of Route Mobile Limited

EIH Limited approves rights issue, fixes Sep 23, 2020 as record date

Hindalco and Hindustan Copper sign MoU for supply of copper concentrate

Kilpest India Limited to merge subsidiary with itself, change name as 3B BlackBio Dx Ltd

Sterling and Wilson Solar Limited Signs order of 106.71 MW worth USD 62.6 mn in Chile

South Korea donates One lakh masks to TVS Motor Company for free distribution to aid India's fight against COVID-19







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019